XML 89 R28.htm IDEA: XBRL DOCUMENT v3.10.0.1
Fair Value Measurements - Assets and Liabilities at Fair Value (Details) - USD ($)
$ in Thousands
Jun. 30, 2018
Dec. 31, 2017
Assets:    
Assets, fair value $ 877,560 $ 188,764
Liabilities:    
Liabilities, fair value 11,800 13,961
Current portion of contingent liabilities - Crystal    
Liabilities:    
Liabilities, fair value 3,618 4,618
Current contingent liabilities-CyDex    
Liabilities:    
Liabilities, fair value 36 86
Long-term portion of contingent liabilities - Crystal    
Liabilities:    
Liabilities, fair value 3,784 3,783
Long-term contingent liabilities-CyDex    
Liabilities:    
Liabilities, fair value 1,503 1,503
Long-term contingent liabilities-Metabasis    
Liabilities:    
Liabilities, fair value 2,859 3,971
Short-term investments    
Assets:    
Assets, fair value 865,264 181,041
Note Receivable - Viking Therapeutics    
Assets:    
Assets, fair value 0 3,877
Investment in Warrants    
Assets:    
Assets, fair value 12,296 3,846
Quoted Prices in Active Markets for Identical Assets (Level 1)    
Assets:    
Assets, fair value 73,689 5,742
Liabilities:    
Liabilities, fair value 0 0
Quoted Prices in Active Markets for Identical Assets (Level 1) | Current portion of contingent liabilities - Crystal    
Liabilities:    
Liabilities, fair value 0 0
Quoted Prices in Active Markets for Identical Assets (Level 1) | Current contingent liabilities-CyDex    
Liabilities:    
Liabilities, fair value 0 0
Quoted Prices in Active Markets for Identical Assets (Level 1) | Long-term portion of contingent liabilities - Crystal    
Liabilities:    
Liabilities, fair value 0 0
Quoted Prices in Active Markets for Identical Assets (Level 1) | Long-term contingent liabilities-CyDex    
Liabilities:    
Liabilities, fair value 0 0
Quoted Prices in Active Markets for Identical Assets (Level 1) | Long-term contingent liabilities-Metabasis    
Liabilities:    
Liabilities, fair value 0 0
Quoted Prices in Active Markets for Identical Assets (Level 1) | Short-term investments    
Assets:    
Assets, fair value 61,393 1,896
Quoted Prices in Active Markets for Identical Assets (Level 1) | Note Receivable - Viking Therapeutics    
Assets:    
Assets, fair value 0 0
Quoted Prices in Active Markets for Identical Assets (Level 1) | Investment in Warrants    
Assets:    
Assets, fair value 12,296 3,846
Significant Other Observable Inputs (Level 2)    
Assets:    
Assets, fair value 803,871 179,145
Liabilities:    
Liabilities, fair value 2,859 3,971
Significant Other Observable Inputs (Level 2) | Current portion of contingent liabilities - Crystal    
Liabilities:    
Liabilities, fair value 0 0
Significant Other Observable Inputs (Level 2) | Current contingent liabilities-CyDex    
Liabilities:    
Liabilities, fair value 0 0
Significant Other Observable Inputs (Level 2) | Long-term portion of contingent liabilities - Crystal    
Liabilities:    
Liabilities, fair value 0 0
Significant Other Observable Inputs (Level 2) | Long-term contingent liabilities-CyDex    
Liabilities:    
Liabilities, fair value 0 0
Significant Other Observable Inputs (Level 2) | Long-term contingent liabilities-Metabasis    
Liabilities:    
Liabilities, fair value 2,859 3,971
Significant Other Observable Inputs (Level 2) | Short-term investments    
Assets:    
Assets, fair value 803,871 179,145
Significant Other Observable Inputs (Level 2) | Note Receivable - Viking Therapeutics    
Assets:    
Assets, fair value 0 0
Significant Other Observable Inputs (Level 2) | Investment in Warrants    
Assets:    
Assets, fair value 0 0
Significant Unobservable Inputs (Level 3)    
Assets:    
Assets, fair value 0 3,877
Liabilities:    
Liabilities, fair value 8,941 9,990
Significant Unobservable Inputs (Level 3) | Current portion of contingent liabilities - Crystal    
Liabilities:    
Liabilities, fair value 3,618 4,618
Significant Unobservable Inputs (Level 3) | Current contingent liabilities-CyDex    
Liabilities:    
Liabilities, fair value 36 86
Significant Unobservable Inputs (Level 3) | Long-term portion of contingent liabilities - Crystal    
Liabilities:    
Liabilities, fair value 3,784 3,783
Significant Unobservable Inputs (Level 3) | Long-term contingent liabilities-CyDex    
Liabilities:    
Liabilities, fair value 1,503 1,503
Significant Unobservable Inputs (Level 3) | Long-term contingent liabilities-Metabasis    
Liabilities:    
Liabilities, fair value 0 0
Significant Unobservable Inputs (Level 3) | Short-term investments    
Assets:    
Assets, fair value 0 0
Significant Unobservable Inputs (Level 3) | Note Receivable - Viking Therapeutics    
Assets:    
Assets, fair value 0 3,877
Significant Unobservable Inputs (Level 3) | Investment in Warrants    
Assets:    
Assets, fair value 0 $ 0
Metabasis | Long-term contingent liabilities-Metabasis    
Liabilities:    
CVR payable to Metabasis $ 3,800